Skip to main content
SpringerLink
Log in

What Do I Do with My Medications If I Become Pregnant? Safety of IBD Medications During Pregnancy

  • Chapter
Inflammatory Bowel Disease

  • 1368 Accesses

Abstract

Many patients worry about how medications used to treat Crohn’s disease or ulcerative colitis will affect pregnancy. While most medications used to treat inflammatory bowel disease (IBD) during pregnancy are low risk, practitioners and patients should be aware of specific adverse effects of certain medications, ideally before becoming pregnant. This chapter discusses the various medications used to treat IBD and the effect they have on pregnancy. We review the literature with regard to use of these medications in both IBD and non-IBD populations. Additionally, a recommendation for use is suggested for each medication.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Borch J, Metzdorff SB, Vinggaard AM, Brokken L, Dalgaard M. Mechanisms underlying the anti-androgenic effects of diethylhexyl phthalate in fetal rat testis. Toxicology. 2006;223(1–2):144–55.

    Article  CAS  PubMed  Google Scholar 

  2. Hernandez-Diaz S, Su YC, Mitchell AA, Kelley KE, Calafat AM, Hauser R. Medications as a potential source of exposure to phthalates among women of childbearing age. Reprod Toxicol. 2013;37:1–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol. 2008;25(2):271–5.

    Article  CAS  PubMed  Google Scholar 

  4. Mahadevan UCD. Aminosalicylate (ASA) use during pregnancy is not associated with increased adverse events or congenital malformations (CM) in women with inflammatory bowel disease (IBD). Gastroenterology. 2006;130 Suppl 2:A40.

    Google Scholar 

  5. Colombel JF, Brabant G, Gubler MC, Locquet A, Comes MC, Dehennault M, et al. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet. 1994;344(8922):620–1.

    Article  CAS  PubMed  Google Scholar 

  6. Mogadam M, Dobbins 3rd WO, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology. 1981;80(1):72–6.

    CAS  PubMed  Google Scholar 

  7. Norgard B, Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT. Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol Ther. 2001;15(4):483–6.

    Article  CAS  PubMed  Google Scholar 

  8. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002;65(5):240–61.

    Article  CAS  PubMed  Google Scholar 

  9. Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations. J Crohns Colitis. 2010;4(1):63–101.

    Article  PubMed  Google Scholar 

  10. Goldstein LH, Dolinsky G, Greenberg R, Schaefer C, Cohen-Kerem R, Diav-Citrin O, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79(10):696–701.

    Article  CAS  PubMed  Google Scholar 

  11. Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol. 2009;85(7):647–54.

    Article  CAS  PubMed  Google Scholar 

  12. Shim L, Eslick GD, Simring AA, Murray H, Weltman MD. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohns Colitis. 2011;5(3):234–8.

    Article  PubMed  Google Scholar 

  13. Coelho J, Beaugerie L, Colombel JF, Hebuterne X, Lerebours E, Lemann M, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut. 2011;60(2):198–203.

    Article  PubMed  Google Scholar 

  14. Casanova MJ, Chaparro M, Domenech E, Barreiro-de Acosta M, Bermejo F, Iglesias E, et al. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108(3):433–40.

    Article  CAS  PubMed  Google Scholar 

  15. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124(1):9–17.

    Article  CAS  PubMed  Google Scholar 

  16. Mahadevan U, Martin C, Sandler RS, et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy [abstract]. Gastroenterology. 2012;142(5 Suppl 1):S-149.

    Google Scholar 

  17. Hoeltzenbein M, Weber-Schoendorfer C, Borisch C, Allignol A, Meister R, Schaefer C. Pregnancy outcome after paternal exposure to azathioprine/6-mercaptopurine. Reprod Toxicol. 2012;34(3):364–9.

    Article  CAS  PubMed  Google Scholar 

  18. Langagergaard V, Pedersen L, Gislum M, Norgard B, Sorensen HT. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther. 2007;25(1):73–81.

    Article  CAS  PubMed  Google Scholar 

  19. Jharap B, de Boer NK, Stokkers P, Hommes DW, Oldenburg B, Dijkstra G, van der Woude CJ, de Jong, Mulder CJ, van Elburg RM, van Bodegraven AA, Dutch Initiative on Crohn and Colitis. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut. 2014; 63(3):451–7.

    Google Scholar 

  20. Rodriguez-Pinilla E, Martinez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology. 1998;58(1):2–5.

    Article  CAS  PubMed  Google Scholar 

  21. Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet. 1999;86(3):242–4.

    Article  CAS  PubMed  Google Scholar 

  22. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–92.

    Article  CAS  PubMed  Google Scholar 

  23. Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol. 2004;18(1):93–101.

    Article  CAS  PubMed  Google Scholar 

  24. Armenti VT, Radomski JS, Moritz MJ, Gaughan WJ, Philips LZ, McGrory CH, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2002:121–30.

    Google Scholar 

  25. Khan AA, Rodriguez A, Kaakinen M, Pouta A, Hartikainen AL, Jarvelin MR. Does in utero exposure to synthetic glucocorticoids influence birthweight, head circumference and birth length? A systematic review of current evidence in humans. Paediatr Perinat Epidemiol. 2011;25(1):20–36.

    Article  PubMed  Google Scholar 

  26. Habal FM, Huang VW. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther. 2012;35(5):501–15.

    Article  CAS  PubMed  Google Scholar 

  27. Beaulieu DB, Ananthakrishnan AN, Issa M, Rosenbaum L, Skaros S, Newcomer JR, et al. Budesonide induction and maintenance therapy for Crohn’s disease during pregnancy. Inflamm Bowel Dis. 2009;15(1):25–8.

    Article  PubMed  Google Scholar 

  28. Baumgart DC, Sturm A, Wiedenmann B, Dignass AU. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut. 2005;54(12):1822–3.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Bertschinger P, Himmelmann A, Risti B, Follath F. Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am J Gastroenterol. 1995;90(2):330.

    CAS  PubMed  Google Scholar 

  30. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001;71(8):1051–5.

    Article  CAS  PubMed  Google Scholar 

  31. Neoral ® [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, NJ; 2013.

    Google Scholar 

  32. Kainz A, Harabacz I, Cowlrick IS, Gadgil SD, Hagiwara D. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation. 2000;70(12):1718–21.

    Article  CAS  PubMed  Google Scholar 

  33. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286–92. quiz e24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99(12):2385–92.

    Article  PubMed  Google Scholar 

  36. Lichtenstein G, Cohen RD, Feagan BG, et al. Safety of infliximab in Crohn’s disease: data from the 5000-patient TREAT Registry. Gastroenterology. 2004;126 Suppl 4:A54.

    Google Scholar 

  37. Heller MM, Wu JJ, Murase JE. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. J Am Acad Dermatol. 2011;65(4):870.

    Article  PubMed  Google Scholar 

  38. Baker DE. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody. Rev Gastroenterol Disord. 2004;4(4):196–210.

    PubMed  Google Scholar 

  39. Jurgens M, Brand S, Filik L, Hubener C, Hasbargen U, Beigel F, et al. Safety of adalimumab in Crohn’s disease during pregnancy: case report and review of the literature. Inflamm Bowel Dis. 2010;16(10):1634–6.

    Article  PubMed  Google Scholar 

  40. Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2014;43:78–84.

    Article  CAS  PubMed  Google Scholar 

  41. Ng SW, Mahadevan U. My treatment approach to management of the pregnant patient with inflammatory bowel disease. Mayo Clin Proc. 2014;89(3):355–60.

    Article  PubMed  Google Scholar 

  42. Johnson DL et al. Pregnancy outcomes for women exposed to adalimumab: OTIS autoimmune diseases in pregnancy project. Arthritis Rheum. 2008;58(9 Suppl): Abstract 1388.

    Google Scholar 

  43. Cristiano L, Friend S, Bozic C, Bloomren G. Evaluation of pregnancy outcomes from the Tysabri (natalizumab) Pregnancy Exposure Registry. Neurology 2013;80 (meeting abstracts 1): P02.127.

    Google Scholar 

  44. Nazareth M, Hogge GS, Cristiano L, Kooijmans M, Mahadevan U. Natalizumab use during pregnancy. Presented at the Annual Meeting of the American College of Gastroenterology. Orlando, FL, USA, 3–8 Oct 2008.

    Google Scholar 

  45. Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71(7):891–5.

    Article  PubMed  Google Scholar 

  46. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17(8):958–63.

    Article  PubMed  Google Scholar 

  47. Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL, BSRBR Control Centre Consortium, et al. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(5):823–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Beghin D, Cournot MP, Vauzelle C, Elefant E. Paternal exposure to methotrexate and pregnancy outcomes. J Rheumatol. 2011;38(4):628–32.

    Article  PubMed  Google Scholar 

  49. Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnenfeld AE, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother. 1998;42(6):1336–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  50. Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol. 1998;105(3):322–7.

    Article  CAS  PubMed  Google Scholar 

  51. Koss CA, Baras DC, Lane SD, Aubry R, Marcus M, Markowitz LE, et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob Agents Chemother. 2012;56(9):4800–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Flagyl ® [Package Insert]. G.D. Searle LLC division of Pfizer Inc., New York, NY; 2013.

    Google Scholar 

  53. Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55(RR-11):1–94.

    Google Scholar 

  54. Lione A. Nonprescription drugs as a source of aluminum, bismuth, and iodine during pregnancy. Reprod Toxicol. 1987–1988;1(4):243-52.

    Google Scholar 

  55. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006;131(1):283–311.

    Article  CAS  PubMed  Google Scholar 

  56. Collins E. Maternal and fetal effects of acetaminophen and salicylates in pregnancy. Obstet Gynecol. 1981;58(5 Suppl):57S–62.

    CAS  PubMed  Google Scholar 

  57. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 7th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2005.

    Google Scholar 

  58. Einarson A, Mastroiacovo P, Arnon J, Ornoy A, Addis A, Malm H, et al. Prospective, controlled, multicentre study of loperamide in pregnancy. Can J Gastroenterol. 2000;14(3):185–7.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Rush University Medical Center, 1725 W. Harrison Street, Suite #206, Chicago, IL, 60612, USA

    Shakthi Dharan Kumar M.D. & Ece A. Mutlu M.D.

Authors
  1. Shakthi Dharan Kumar M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ece A. Mutlu M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shakthi Dharan Kumar M.D. .

Editor information

Editors and Affiliations

  1. Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

    Daniel J. Stein

  2. Chief, Division Gastroenterology and Hepatology Digestive Disease Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

    Reza Shaker

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Kumar, S.D., Mutlu, E.A. (2015). What Do I Do with My Medications If I Become Pregnant? Safety of IBD Medications During Pregnancy. In: Stein, D., Shaker, R. (eds) Inflammatory Bowel Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-14072-8_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-14072-8_23

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-14071-1

  • Online ISBN: 978-3-319-14072-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation